AskBio Advances Gene Therapy Clinical Trial for Limb-Girdle Muscular Dystrophy Type 2I/R9 with Dosing of First Participant in Second Cohort
March 07, 2025 08:00 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Research Triangle Park, N.C., March 07, 2025 (GLOBE NEWSWIRE) -- Data Safety Monitoring Board (DSMB) recommendation to initiate second cohort follows review of Phase 1/Phase 2 LION-CS101 trial...
AskBio Receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’s disease investigational gene therapy
February 19, 2025 08:00 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, N.C., USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Not intended for UK Media Regenerative Medicine Advanced Therapy (RMAT) designation follows Phase Ib...
First Participant Randomized in AskBio European Phase 2 Gene Therapy Trial for Congestive Heart Failure
February 13, 2025 08:00 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Research Triangle Park, N.C., Feb. 13, 2025 (GLOBE NEWSWIRE) -- AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart...
First participants randomized in AskBio Phase II gene therapy trial for Parkinson’s disease
January 14, 2025 08:00 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, N.C., USA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Not intended for UK Media Enrollment ongoing in the United States for REGENERATE-PD clinical trial of...
AskBio Receives FDA Rare Pediatric Disease and Orphan-Drug Designations for AB-1003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9
November 07, 2024 08:07 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Research Triangle Park, N.C., Nov. 07, 2024 (GLOBE NEWSWIRE) -- First patient dosed in Phase 1/Phase 2 LION-CS101 trial of AB-1003 in August 2023, with enrollment continuing Asklepios...
AskBio Announces 11 Presentations at the European Society of Gene and Cell Therapy 31st Annual Meeting 2024
October 17, 2024 08:00 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Research Triangle Park, N.C., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Two oral presentations and nine poster presentations will highlight exciting progress in AskBio’s clinical and pre-clinical...
AskBio to collaborate with Belief BioMed to explore the potential of new gene therapies
September 25, 2024 08:00 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, N.C., USA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AskBio and Belief BioMed will work together to advance potential gene...
AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson’s disease
July 11, 2024 08:00 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, N.C., USA, July 11, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1005 (formerly known as AAV2-GDNF) is being studied for the treatment of...
AskBio Initiates Recruitment to its Phase 2 Parkinson’s Disease Trial
June 25, 2024 08:00 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Research Triangle Park, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- REGENERATE-PD, which is now enrolling, will study AB-1005, an adeno-associated virus 2 (AAV2) glial cell line-derived neurotrophic...
AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting 2024
May 02, 2024 08:00 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Research Triangle Park, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG,...